Somatostatin receptor gene therapy combined with targeted therapy with radiolabeled octreotide: A new treatment for liver metastases

Annals of Surgery

Volumn 236, Issue 6, 2002, Pages 722-729

  Mearadji, Amir ^a   Breeman, Wout ^a   Hofland, Leo ^a   Van Koetsveld, Peter ^a   Marquet, Richard ^a   Jeekel, Johannes ^a   Krenning, Eric ^a   Van Eijck, Casper ^a   Broelsch, C E ^b   Mearadij, A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; LUTETIUM; OCTREOTATE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177]; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; BETA RADIATION; BYSTANDER EFFECT; CANCER RADIOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; GENE THERAPY; GENETIC TRANSDUCTION; ISOTOPE LABELING; LIVER METASTASIS; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCORING SYSTEM;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENE THERAPY; INDIUM RADIOISOTOPES; LIVER; LIVER NEOPLASMS; MALE; NEOPLASM TRANSPLANTATION; OCTREOTIDE; PROBABILITY; RATS; RATS, INBRED STRAINS; RECEPTORS, SOMATOSTATIN; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0036896890     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200212000-00004     Document Type: Article

References (22)

1. Reubi JC, Laissue J, Krenning E, et al. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43:27-35.
2. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93:1321-5.
3. Hofland LJ, Lamberts SW. Somatostatin analogs and receptors. Diagnostic and therapeutic applications. Cancer Treat Res 1997; 89:365-382.
4. Krenning EP, Valkema R, Kooij PP, et al. The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res 2000; 153:1-13.
5. 111In-pentetreotide: Initial observations and future directions. Cancer J Sci Am 1998; 4:94-102.
6. 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000; 21:97-102.
7. 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. South Med J 2000; 93:809-11.
8. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999; 26:1439-47.
9. 90Y-SMT487; OctreoTher): A phase I study. J Nucl Med 2000; 41:111P.
10. 90Y-DOTA-D-Phe1-Tyr3-Octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm 1999; 14:477-483.
11. 90Y-DOTA-D-Phel-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426-434.
12. 111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001; 28:1319-1325.
13. 177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92:628-33.
14. Marquet RL, Westbroek DL, Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: Importance of tumor site. Int J Cancer 1984; 33:689-692.
15. Slooter GD, Breeman WA. Marquet RL, et al.Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 1999; 81:767-771.
16. Slooter GD, Aalbers AG, Breeman WA, et al. The inhibitory effect of radiolabelled octreotide on intrahepatic tumour growth after partial hepatectomy. J Nucl Med. 2002 (in press).
17. Mearadji A, Breeman WA, Hofland LJ, et al. The effect of targeted therapy with radiolabelled octreotide on somatostatin receptor transfected colon carcinoma cells in a rat liver metastases model. Eur Surg Res 2001; 33:164.
18. Reubi JC, Torhorst J. The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer. Cancer 1989; 64:1254-1260.
19. de Jong M, Bakker WH, Breeman WA, et al. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998; 75:406-411.
20. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998; 58:437-441.
21. 177lutetium-labeled immunoconjugate. Cancer Res 1991; 51:2889-2896.
22. Lewis JS, Wang M, Laforest R, et al. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer 2001; 94:873-877.